ARTICLE | Editor's Commentary
JPM brings throwback vibes, and optimism outweighing the gloom: a Perspective
The buzz of Asia innovation and upbeat hopes for deals outshadow concerns over IPOs, FDA and more. Fewer people, better meetings
January 18, 2025 1:24 AM UTC
This year’s JPM vibe was a throwback to the days before the huge boom, launching the year with high energy among attendees and not much trouble finding a place to meet in a coffee shop. I’d argue it’s a signal of the next phase in biotech, marked by fewer companies, more frugality, and maybe even less FOMO.
The hottest topic, far and away, was cross-border deals and the rising profile of Asia innovation and assets from China biotechs. ...